Skip to main content

Summary

for people ages 18–70 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in adults with primary sclerosing cholangitis (PSC).

Official Title

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis

Keywords

Primary Sclerosing Cholangitis

Eligibility

For people ages 18–70

Key Inclusion Criteria:

  • Diagnosis of PSC based on cholangiogram (magnetic resonance cholangiopancreatography(MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous transhepatic cholangiogram (PTC)) within the previous 12 months
  • Serum alkaline phosphatase (ALP)> 1.67 x upper limit of the normal range (ULN)
  • For individuals on ursodeoxycholic acid (UDCA), the dose of UDCA must have been stable for at least 12 months prior to screening through the end of treatment. For individuals not on UDCA, no UDCA use for at least 12 months before screening through the end of treatment
  • Screening FibroSURE/FibroTest® <0.75 unless a historical liver biopsy within 12 months of screening does not reveal cirrhosis. In adults with Gilbert's syndrome or hemolysis, FibroSURE/FibroTest® will be calculated using direct bilirubin instead of total bilirubin.

Key Exclusion Criteria:

  • Alanine aminotransferase (ALT)> 10 x ULN
  • Total bilirubin> 2 x ULN
  • International normalized ratio (INR)> 1.2 unless on anticoagulant therapy
  • Small-duct PSC (histologic evidence of PSC with normal bile ducts on cholangiography)
  • Other causes of liver disease including secondary sclerosing cholangitis and viral,metabolic, alcoholic, and other autoimmune conditions
  • Ascending cholangitis within 60 days of screening
  • Presence of a percutaneous drain or bile duct stent
  • Use of fibrates or obeticholic acid within 3 months prior to screening through the end of treatment
  • Cirrhosis of the liver as defined by any of the following:
  • Historical liver biopsy demonstrating cirrhosis (eg, Ludwig stage 4 or Ishak stage ≥ 5)
  • Prior history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding
  • Liver stiffness> 14.4 kPa by FibroScan
  • Current, active inflammatory bowel disease (IBD) defined as a partial Mayo score of> 1 and/or a score on the Rectal Bleeding domain> 0.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

  • San Francisco, California, United States
  • Fresno, California, United States
  • Sacramento, California, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Gilead Sciences
ID
NCT02943460
Phase
Phase 2
Lead Scientist
Bilal Hameed
Study Type
Interventional
Last Updated
July 1, 2017
I’m interested in this study!